CoChat

Antipsychotic Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: An Update Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials

Open access
Dold, Markus, Aigner, Martin, Lanzenberger, Rupert, Kasper, Siegfried · 2015 · International Journal of Neuropsychopharmacology

The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.

Abstract

Many patients with obsessive-compulsive disorder do not respond adequately to serotonin reuptake inhibitors. Augmentation with antipsychotic drugs can be beneficial in this regard. However, since new relevant randomized controlled trials evaluating new antipsychotics were conducted, a recalculation of the effect sizes appears necessary. We meta-analyzed all double-blind, randomized, placebo-controlled trials comparing augmentation of serotonin reuptake inhibitors with antipsychotics to placebo supplementation in treatment-resistant obsessive-compulsive disorder. The primary outcome was mean change in the Yale-Brown Obsessive–Compulsive Scale total score. Secondary outcomes were obsessions, compulsions, response rates, and attrition rates. The data collection process was conducted independently by 2 authors. Hedges’s g and risks ratios were calculated as effect sizes. In preplanned meta-regressions, subgroup analyses, and sensitivity analyses, we examined the robustness of the results and explored reasons for potential heterogeneity. Altogether, 14 double-blind, randomized, placebo-controlled trials (n=491) investigating quetiapine (N=4, n=142), risperidone (N=4, n=132), aripiprazole (N=2, n=79), olanzapine (N=2, n=70), paliperidone (N=1, n=34), and haloperidol (N=1, n=34) were incorporated. Augmentation with antipsychotics was significantly more efficacious than placebo in Yale-Brown Obsessive–Compulsive Scale total reduction (N=14, n=478; Hedges’s g=-0.64, 95% CI: -0.87 to -0.41; P=<.01). Aripiprazole (Hedges’s g=-1.35), haloperidol (Hedges’s g=-0.82), and risperidone (Hedges’s g=-0.59) significantly outperformed placebo. Antipsychotics were superior to placebo in treating obsessions, compulsions, and achieving response. There was no between-group difference concerning all-cause discontinuation. The nonsignificant meta-regressions suggest no influence of the antipsychotic dose or baseline symptom severity on the meta-analytic results. According to our findings, antipsychotic augmentation of serotonin reuptake inhibitors can be regarded as an evidence-based measure in treatment-resistant obsessive-compulsive disorder.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/ijnp/pyv047

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Flowchart of the systematic update literature search according to the PRISMA statement (Moher et al., 2009).
Figure 1. Flowchart of the systematic update literature search according to the PRISMA statement (Moher et al., 2009).CC BY-NC · PubMed Central
Figure 2. Effect sizes for the primary outcome mean change in Y-BOCS total scores from baseline to study endpoint. Comparison: antipsychotic augmentation vs placebo augmentation. The forest plot illustrates the standardized mean differences based on Hedges’s g with the corresponding 95% CIs. Numerical values <0 indicate a higher Yale–Brown Obsessive–Compulsive Scale (Y-BOCS) reduction in the antipsychotic group compared to the control group. Statistical significance can be assumed if the 95% CI does not comprise the numerical value of 0 and/or if the P-value of the comparison is <.05.
Figure 2. Effect sizes for the primary outcome mean change in Y-BOCS total scores from baseline to study endpoint. Comparison: antipsychotic augmentation vs placebo augmentation. The forest plot illustrates the standardized mean differences based on Hedges’s g with the corresponding 95% CIs. Numerical values <0 indicate a higher Yale–Brown Obsessive–Compulsive Scale (Y-BOCS) reduction in the antipsychotic group compared to the control group. Statistical significance can be assumed if the 95% CI does not comprise the numerical value of 0 and/or if the P-value of the comparison is <.05.CC BY-NC · PubMed Central
Figure 3. Effect sizes for the response rates (preferably ≥35% Y-BOCS total improvement during the double-blind augmentation phase). Comparison: antipsychotic augmentation vs placebo augmentation. The forest plot illustrates the Mantel-Haenszel (MH) risk ratios with the corresponding 95% CIs. Numerical values >1 indicate a higher proportion of responders in the antipsychotic group compared to the control group. Statistical significance is present if the 95% CI does not include the numerical value of 1 and/or if the P-value of the comparison is <.05.
Figure 3. Effect sizes for the response rates (preferably ≥35% Y-BOCS total improvement during the double-blind augmentation phase). Comparison: antipsychotic augmentation vs placebo augmentation. The forest plot illustrates the Mantel-Haenszel (MH) risk ratios with the corresponding 95% CIs. Numerical values >1 indicate a higher proportion of responders in the antipsychotic group compared to the control group. Statistical significance is present if the 95% CI does not include the numerical value of 1 and/or if the P-value of the comparison is <.05.CC BY-NC · PubMed Central
Figure 4. Effect sizes for the drop-out rate due to any reason (all-cause discontinuation). Comparison: antipsychotic augmentation vs placebo augmentation. The forest plot illustrates the Mantel-Haenszel (MH) risk ratios with the corresponding 95% CIs. Numerical values >1 indicate a higher attrition rate in the antipsychotic group compared with the control group.
Figure 4. Effect sizes for the drop-out rate due to any reason (all-cause discontinuation). Comparison: antipsychotic augmentation vs placebo augmentation. The forest plot illustrates the Mantel-Haenszel (MH) risk ratios with the corresponding 95% CIs. Numerical values >1 indicate a higher attrition rate in the antipsychotic group compared with the control group.CC BY-NC · PubMed Central
Figure 5. Unrestricted maximum-likelihood meta-regression with mean olanzapine equivalents as continuous moderator variable. Hedges’s g refers to the effect sizes of the primary outcome (mean Yale–Brown Obsessive–Compulsive Scale [Y-BOCS] total score change). The olanzapine dose equivalents were calculated following the International Consensus Study of Antipsychotic Dosing (Gardner et al., 2010). The circle size reflects the weight a study obtained in this meta-regression. Slope=0.0002, 95% CI: -0.09 to 0.09; P=.996.
Figure 5. Unrestricted maximum-likelihood meta-regression with mean olanzapine equivalents as continuous moderator variable. Hedges’s g refers to the effect sizes of the primary outcome (mean Yale–Brown Obsessive–Compulsive Scale [Y-BOCS] total score change). The olanzapine dose equivalents were calculated following the International Consensus Study of Antipsychotic Dosing (Gardner et al., 2010). The circle size reflects the weight a study obtained in this meta-regression. Slope=0.0002, 95% CI: -0.09 to 0.09; P=.996.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 49 references

Research works printed but not linked: 2

  1. Borenstein, 2006, Comprehensive meta-analysis, version 2
  2. The Cochrane Collaboration, 2014, Review Manager (RevMan) [Computer program]. Version 5.3

Cited by

Metadata

Authors
Dold, M., Aigner, M., Lanzenberger, R., & Kasper, S.
Affiliations
Universitätsklinikum Tulln (AT)
Corresponding author
Kasper, Siegfried
Venue
International Journal of Neuropsychopharmacology
Published
2015-05-04
Volume
18
Issue
9
Pages
pyv047
ISSN
  • 1461-1457 (ISSN-L)
  • 1469-5111
OpenAlex
W4244844159
Cited by
134
References
49
Citations by year
2026: 19 · 2025: 11 · 2024: 16 · 2023: 7 · 2022: 8 · 2021: 12 · 2020: 16 · 2019: 16 · 2018: 10 · 2017: 11 · 2016: 7 · 2015: 1
FWCI
1.40
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • The International Journal of Neuropsychopharmacology (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • HighWire Press Open Archive (submittedVersion)
Funders
  • Eli Lilly and Company
  • Pfizer
  • AstraZeneca
  • GlaxoSmithKline
  • Servier
  • H. Lundbeck A/S
  • Cilag
Topics
  • Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Social Sciences › Psychology › Clinical Psychology › Psychoanalysis and Psychopathology Research
Keywords
treatment-resistant OCD, antipsychotic augmentation, serotonin reuptake inhibitors, quetiapine, risperidone, aripiprazole, olanzapine, paliperidone, haloperidol, Yale-Brown Obsessive Compulsive Scale, obsessions and compulsions, treatment response, attrition, antipsychotic dosing

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.